PriceTargets.com logo

Ipsen - IPSEY Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00%
  • Number of Analysts: 1
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$28.72 As of 04/18/2024 01:00 AM ET
▲ +0.1 (0.35%)

This chart shows the closing price for IPSEY by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Ipsen Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for IPSEY and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for IPSEY

Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 1 analysts offering 12 month price targets for Ipsen in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $28.72.

This chart shows the closing price for IPSEY for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 1 contributing investment analysts is to buy stock in Ipsen. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/27/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/25/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/25/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
7/24/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/22/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/20/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/20/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/19/2024

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
9/12/2023UBS GroupUpgradeNeutral ➝ Buy
2/16/2023Morgan StanleyUpgradeUnderweight ➝ Equal Weight
1/12/2023Deutsche Bank AktiengesellschaftBoost TargetHold ➝ Hold€90.00 ➝ €95.00
12/9/2022Oddo BhfDowngradeOutperform ➝ Neutral
12/6/2022BarclaysReiterated RatingEqual Weight ➝ Equal Weight
12/2/2022Jefferies Financial GroupInitiated CoverageBuy
11/21/2022JPMorgan Chase & Co.Boost TargetC$91.00 ➝ C$115.00
11/4/2022UBS GroupBoost Target€102.00 ➝ €107.00
10/31/2022Societe GeneraleBoost TargetBuy ➝ Buy€139.00 ➝ €142.00
10/31/2022Royal Bank of CanadaBoost Target€107.00 ➝ €108.00
10/13/2022Morgan StanleyBoost TargetUnderweight ➝ Underweight€84.00 ➝ €86.00
9/28/2022Royal Bank of CanadaInitiated CoverageSector Perform
8/26/2022CheuvreuxUpgradeHold ➝ Buy€110.00
8/2/2022Berenberg BankBoost TargetHold ➝ Hold€98.00 ➝ €102.00
8/1/2022Credit Suisse GroupBoost Target€95.00 ➝ €100.00
7/20/2022UBS GroupLower TargetNeutral ➝ Neutral€117.00 ➝ €102.00
4/29/2022Societe GeneraleBoost TargetBuy ➝ Buy€112.00 ➝ €120.00
4/27/2022Bryan, Garnier & CoDowngradeBuy ➝ Neutral
4/14/2022BarclaysBoost TargetUnderweight ➝ Underweight€88.00 ➝ €95.00
3/25/2022Credit Suisse GroupBoost TargetNeutral ➝ Neutral€87.00 ➝ €105.00
2/22/2022BarclaysBoost TargetUnderweight ➝ Underweight€78.00 ➝ €88.00
2/17/2022AlphaValueUpgradeReduce
1/11/2022UBS GroupUpgradeNeutral ➝ Buy
1/6/2022Societe GeneraleUpgradeHold ➝ Buy
1/4/2022JPMorgan Chase & Co.DowngradeOverweight ➝ Neutral
11/24/2021Berenberg BankInitiated CoverageHold
11/5/2021Morgan StanleyDowngradeEqual Weight ➝ Underweight
10/22/2021Credit Suisse GroupReiterated RatingNeutral
10/19/2021Exane BNP ParibasInitiated CoverageNeutral
10/19/2021BarclaysDowngradeOverweight ➝ Underweight
10/11/2021JPMorgan Chase & Co.Reiterated RatingOverweight
10/7/2021Morgan StanleyReiterated RatingEqual Weight
8/16/2021Morgan StanleyReiterated RatingEqual Weight
8/3/2021Morgan StanleyReiterated RatingEqual Weight
8/2/2021Societe GeneraleReiterated RatingHold
7/30/2021Credit Suisse GroupReiterated RatingNeutral
6/29/2021Societe GeneraleReiterated RatingHold
6/14/2021Societe GeneraleDowngradeBuy ➝ Hold
5/28/2021BarclaysReiterated RatingOverweight
5/27/2021JPMorgan Chase & Co.Reiterated RatingOverweight
4/23/2021Societe GeneraleReiterated RatingBuy
4/20/2021Deutsche Bank AktiengesellschaftInitiated CoverageHold
2/16/2021BarclaysReiterated RatingOverweight
1/14/2021Societe GeneraleUpgradeHold ➝ Buy
12/8/2020Morgan StanleyDowngradeOverweight ➝ Equal Weight
12/4/2020Bank of AmericaDowngradeBuy ➝ Neutral
12/2/2020Bryan, Garnier & CoDowngradeBuy ➝ Neutral
10/26/2020BarclaysUpgradeEqual Weight ➝ Overweight
9/1/2020Morgan StanleyReiterated RatingOverweight
8/4/2020UBS GroupReiterated RatingBuy
8/3/2020Credit Suisse GroupReiterated RatingNeutral
7/31/2020BarclaysReiterated RatingEqual Weight
7/22/2020JPMorgan Chase & Co.UpgradeNeutral ➝ Overweight
7/16/2020Societe GeneraleDowngradeBuy ➝ Hold
7/14/2020Morgan StanleyReiterated RatingOverweight
6/1/2020BarclaysReiterated RatingEqual Weight
6/1/2020Bank of AmericaUpgradeNeutral ➝ Buy
5/18/2020JPMorgan Chase & Co.UpgradeUnderweight ➝ Neutral
4/22/2020UBS GroupReiterated RatingBuy
4/20/2020BarclaysReiterated RatingEqual Weight
2/11/2020Credit Suisse GroupUpgradeUnderperform ➝ Neutral
1/9/2020Jefferies Financial GroupDowngradeBuy ➝ Hold
1/5/2020JPMorgan Chase & Co.DowngradeNeutral ➝ Underweight
12/9/2019BarclaysDowngradeOverweight ➝ Equal Weight
5/20/2019JPMorgan Chase & Co.UpgradeUnderweight ➝ Neutral
(Data available from 4/19/2019 forward)

News Sentiment Rating

-0.12 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 2 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/22/2023
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/22/2023
  • 2 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/21/2023
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/21/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/20/2024
  • 2 very positive mentions
  • 9 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
2/19/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/20/2024
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
4/19/2024

Current Sentiment

  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 1 very negative mentions

Recent Stories by Sentiment

Very Negative

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

  • No very positive mentions tracked during this time.
Ipsen logo
Ipsen S.A. operates as a biopharmaceutical company worldwide. The company provides drugs in the areas of oncology, neuroscience, and rare diseases. Its product pipeline comprises Cabometyx + Atezolizumab, which is in phase III clinical trial for the treatment of second line metastatic castration-resistant prostate cancer; lenalidomide and rituximab, and Taverik, which is in phase III for the treatment of second line follicular lymphoma; Bylvay, which is in phase III for the treatment of biliary atresia; Dysport, which is in phase III clinical trial for the treatment of chronic and episodic migraine; Fidrisertib, which is in phase II clinical trial for the treatment of fibrodysplasia ossificans progressiva; Elafibranor, which is in phase II for the treatment of primary sclerosing cholangitis, as well as IPN60250; IPN10200, which is in phase II for the treatment of longer-acting neurotoxin aesthetics and therapeutics; IPN60210, which is in phase I clinical trial for the treatment of relapsed/refractory multiple myeloma; and IPN60260 for the treatment of Viral cholestatic disease and is in phase I clinical trial. The company also offers Somatuline, Decapeptyl, Cabometyx, Onivyde, Tazverik, and other oncology products; Dysport and other neurosciences products; and Bylvay, NutropinAq, Increlex, and Sohonos for rare diseases. The company was founded in 1929 and is based in Boulogne-Billancourt, France.
Read More

Today's Range

Now: $28.72
Low: $28.72
High: $28.72

50 Day Range

MA: $28.81
Low: $27.50
High: $30.34

52 Week Range

Now: $28.72
Low: $26.97
High: $34.34

Volume

491 shs

Average Volume

2,141 shs

Market Capitalization

N/A

P/E Ratio

N/A

Dividend Yield

0.81%

Beta

0.92

Frequently Asked Questions

What sell-side analysts currently cover shares of Ipsen?

The following sell-side analysts have issued stock ratings on Ipsen in the last twelve months: UBS Group AG.
View the latest analyst ratings for IPSEY.

What is the current price target for Ipsen?

0 Wall Street analysts have set twelve-month price targets for Ipsen in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for Ipsen in the next year.
View the latest price targets for IPSEY.

What is the current consensus analyst rating for Ipsen?

Ipsen currently has 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe IPSEY will outperform the market and that investors should add to their positions of Ipsen.
View the latest ratings for IPSEY.

What other companies compete with Ipsen?

Other companies that are similar to Ipsen include 1933 Industries, 4Cable TV International, 4Front Ventures, AB Science and Abacus Health Products. Learn More about companies similar to Ipsen.

How do I contact Ipsen's investor relations team?

Ipsen's physical mailing address is 65 quai Georges Gorse, Boulogne-Billancourt cedex I0, 92650. The company's listed phone number is (315) 833-5000 and its investor relations email address is [email protected]. The official website for Ipsen is www.ipsen.com. Learn More about contacing Ipsen investor relations.